Crispr Therapeutics AG (NASDAQ:CRSP) has been given a consensus recommendation of “Hold” by the sixteen research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $57.50.

CRSP has been the topic of several research analyst reports. Barclays increased their price target on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. BidaskClub cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 11th. Canaccord Genuity initiated coverage on shares of Crispr Therapeutics in a research report on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 price target on shares of Crispr Therapeutics in a research report on Wednesday, July 31st. Finally, Roth Capital increased their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research report on Tuesday, July 30th.

Shares of CRSP stock traded up $2.14 during trading hours on Wednesday, hitting $40.05. 771,655 shares of the company were exchanged, compared to its average volume of 607,097. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.96 and a current ratio of 13.96. Crispr Therapeutics has a one year low of $22.22 and a one year high of $53.90. The business’s 50-day simple moving average is $43.30 and its two-hundred day simple moving average is $43.33. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -11.64 and a beta of 3.11.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, July 29th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.84). Crispr Therapeutics had a negative return on equity of 51.49% and a negative net margin of 15,136.56%. The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $47.57 million. During the same period in the previous year, the business posted ($0.82) EPS. The business’s revenue for the quarter was down 70.8% on a year-over-year basis. As a group, analysts anticipate that Crispr Therapeutics will post -3.85 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. raised its stake in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc raised its stake in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE raised its stake in Crispr Therapeutics by 553.7% during the second quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics during the third quarter worth about $26,000. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics during the second quarter worth about $39,000. Hedge funds and other institutional investors own 50.23% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What is a Derivative?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.